The complaint also alleged that pharmacies could earn discounts for recommending that doctors switch patients to Myfortic from competing drugs. Regulators focused on the fact that the discounts were not based only on whether the pharmacy purchased the product. Additionally, the government contended that Novartis induced specialty pharmacy referrals by giving deeper rebates to pharmacies that obtained higher refill rates. The amended complaint referenced a Novartis PowerPoint that encouraged sales reps to "offer discounts to drive refills." The case resulted in more than $430 million in combined settlement payments among the defendants. Johnson & Johnson [J&J] paid $2.2 billion and Omnicare paid $124.4 million to settle claims that, among other things, J&J paid Omnicare for data as a substitute for discounts and that discounts on Risperdal were based on Omnicare's market share of the drug.